EUVIMEDEUVIMED entdecken
Crossref

Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer

Tatsuya Ito iD, Go Omura iD, Chihiro Fushimi, Toshihiko Sakai iD, Azusa Sakai iD, Kohtaro Eguchi iD, Takaaki Hayashi, Takane Watanabe iD, Akihisa Tanaka iD, Mitsuhiko Katoh iD, Hiroshi Imazeki, Shun Yamamoto und 4 weitere

Head & Neck · 2026

DOI: 10.1002/hed.70326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Tatsuya Ito und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Hypopharyngeal Neoplasms. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the therapeutic effect of neoadjuvant docetaxel, cisplatin, and 5‐fluorouracil (NeoDCF), the standard treatment for stage IB–III esophageal squamous cell carcinoma (ESCC), against synchronous superficial pharyngeal squamous cell carcinoma (PSCC).

Methods

We retrospectively reviewed ESCC patients with synchronous early‐stage PSCC who received NeoDCF. The primary endpoint was disease‐specific survival (DSS) for PSCC. Secondary endpoints included overall survival (OS), local tumor response, and time to progression (TTP) of PSCC.

Results

Among 786 patients with ESCC, 58 (7.4%) had synchronous early‐stage PSCC. Local tumor response was complete disappearance in 33 (57%) patients, partial reduction in 24 (41%), and no change in 1 (2%). The 3‐year DSS, OS, and TTP were 100%, 61%, and 78%, respectively. No significant difference was found between the Tis and T1/T2 groups ( p = 0.67).

Conclusions

NeoDCF demonstrated excellent efficacy against early‐stage PSCC, supporting prioritization of ESCC treatment with timely local intervention for recurrent PSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellHypopharyngeal NeoplasmsOropharyngeal NeoplasmsNeoplasms, Multiple PrimaryHumansFluorouracilCisplatinDocetaxelRetrospective StudiesNeoadjuvant TherapyFemaleMaleMiddle AgedTaxoidsNeoplasm StagingAgedTreatment OutcomeAdult

Stichwörter der Autor:innen

esophageal squamous cell carcinomahead and neck squamous cell carcinomaneoadjuvant docetaxel, cisplatin, and 5‐fluorouracilsuperficial carcinomasynchronous primary cancer

Substanzen

FluorouracilCisplatinDocetaxelTaxoids

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Tatsuya Ito, Go Omura, Toshihiko Sakai, Azusa Sakai, Kohtaro Eguchi, Takane Watanabe, Akihisa Tanaka, Mitsuhiko Katoh, Yoshitaka Honma, Hideaki Takahashi, Ken Kato, Seiichi Yoshimoto

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Ito, T., Omura, G., Fushimi, C., Sakai, T., Sakai, A., Eguchi, K., Hayashi, T., Watanabe, T., Tanaka, A., Katoh, M., Imazeki, H., Yamamoto, S., Honma, Y., Takahashi, H., Kato, K., & Yoshimoto, S. (2026). Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer. Head & Neck. https://doi.org/10.1002/hed.70326

Vancouver

Ito T, Omura G, Fushimi C, Sakai T, Sakai A, Eguchi K, et al. Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer. Head & Neck. 2026. doi:10.1002/hed.70326

BibTeX
@article{Ito2026,
  author = {Ito, Tatsuya and Omura, Go and Fushimi, Chihiro and Sakai, Toshihiko and Sakai, Azusa and Eguchi, Kohtaro and Hayashi, Takaaki and Watanabe, Takane and Tanaka, Akihisa and Katoh, Mitsuhiko and Imazeki, Hiroshi and Yamamoto, Shun and Honma, Yoshitaka and Takahashi, Hideaki and Kato, Ken and Yoshimoto, Seiichi},
  title = {Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70326}
}
Kostenlos starten →